Last reviewed · How we verify

NCT06385067

Treatment of Primary Coronary Artery Vascular Lesions With Biolimus Coated Coronary Balloon Dilation Catheter

Not yet recruiting Last updated 25 April 2024
What this trial tests

trial testing Biolimus Coated Coronary Artery Balloon Dilation Catheter in Coronary Artery Disease in 400 participants. Not yet recruiting.

Timeline
10 May 2024
Primary endpoint
30 December 2025
30 December 2026

Quick facts

Lead sponsorJW Medical Systems Ltd
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment400
Start date10 May 2024
Primary completion30 December 2025
Estimated completion30 December 2026

Drugs / interventions tested

Conditions studied

Sponsor

JW Medical Systems Ltd

Who can join

18 and older, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study was to further evaluate the long-term safety and efficacy of the Biolimus Coated Coronary Artery Balloon Dilation Catheter in the real world. The study population was patients with primary coronary vascular lesions with a blood vessel diameter of 2.0mm-2.75mm.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other JW Medical Systems Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06385067.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing